AstraZeneca updates on olaparib and TC-5214 development programmes
20 December 2011 | By AstraZeneca
With associated impairment charges, company confirms full year financial target...
List view / Grid view
News
Roche’s personalised medicine Zelboraf receives positive opinion from European authority
19 December 2011 | By Roche
For the treatment of people with BRAF mutation-positive metastatic melanoma...
Pfizer reports positive results from Phase 3 trial Of Lyrica (pregabaline)
19 December 2011 | By Pfizer
Patients with Restless Legs Syndrome (RLS) show significant benefit...
GSK extends pneumococcal vaccine agreement with GAVI Alliance
19 December 2011 | By GlaxoSmithKline
Move aims to protect millions more children in the world's poorest countries from pneumococcal disease...
Sharer to step down as chairman and chief executive officer of Amgen
19 December 2011 | By Amgen
Kevin W. Sharer has announced his plan to retire from the Company at the end of 2012...
Simcere and Bristol-Myers Squibb enter innovative partnership to develop cardiovascular compound
15 December 2011 | By
The companies have expanded the strategic partnership formed last year...
New Intrauterine System for long-term contraception submitted for marketing authorization both in the EU and the U.S.
15 December 2011 | By Bayer HealthCare
Once approved, the new low dose IUS will offer contraception for up to three years...
Final results from largest phase 3 open-label study assessing Nplate®
15 December 2011 | By Amgen
Additional key Nplate (Romiplostim) data also presented at American Society of Hematology annual meeting...
Merck announces initiation of clinical development collaboration with Roche
15 December 2011 | By Merck
New clinical trial will evaluate an investigational therapeutic regimen with VICTRELIS™ (boceprevir)...
Changes to the Roche Corporate Executive Committee
15 December 2011 | By Roche
Roche announced that Sophie Kornowski-Bonnet has been appointed Head of Roche Partnering...
Novartis drug Gilenya® showed positive clinical outcomes for relapsing-remitting MS patients in third large Phase III clinical trial
15 December 2011 | By Novartis
Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study...
GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus
15 December 2011 | By GlaxoSmithKline
Study to enrol over 800 adult patients with systemic lupus erythematosus...
G-BA issues positive final medical benefit assessment for BRILIQUE in Germany
15 December 2011 | By AstraZeneca
AstraZeneca announced that the German assessment body, the Federal Joint Committee (G-BA), has issued its final decision regarding the medical benefit of BRILIQUE (ticagrelor)...
Syrris chemical reactors – good under pressure
14 December 2011 | By kdm communications limited
Syrris, offers a range of reactors designed specifically for applications requiring elevated pressures...
Boehringer Ingelheim significantly expands its supply center for China
14 December 2011 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the company intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai...
